唇裂修复术后预防性抗生素是否必要:并发症减少与风险分层
基于2021-2024年美国外科医师学会儿科SAP数据,回顾性分析4966例≤12月龄原发性唇裂修复患儿。总体SSI率0.7%,预防性抗生素(SAP)与SSI、再入院或复合并发症减少均无关;但双侧唇裂亚组中SAP与SSI几率显著降低相关。
要点
- 总体唇裂修复患儿中SAP未显著降低SSI、再入院或复合并发症。
- 双侧唇裂亚组接受SAP者SSI几率显著降低,提示高危亚组可能获益。
- 90.4%患儿接受SAP,最常用头孢唑林(87.2%),总体SSI率0.7%。
核心结论
- 总体唇裂修复人群中SAP与并发症减少无关。
- 双侧唇裂亚组接受SAP者SSI几率显著降低,可能从预防性抗生素中获益。
研究设计与样本
- 回顾性队列研究,使用2021-2024年美国外科医师学会儿科SAP数据文件。
- 纳入≤12月龄原发性唇裂修复患儿4966例,分三组:无SAP、SAP无术后继续、SAP术后继续静脉抗生素。
- 主要结局为30天SSI和再入院,采用Firth惩罚逻辑回归评估。
- 预设亚组分析针对双侧唇裂修复患者。
主要发现
- 475例(9.6%)无SAP,3250例(65.4%)SAP无继续,1241例(25.0%)SAP术后继续。
- 总体SSI率0.7%,SAP使用率90.4%,头孢唑林占87.2%。
- 多变量分析:SAP无继续组SSI的OR 0.69(95%CI 0.27-2.19,p=0.49),SAP继续组OR 0.61(95%CI 0.20-2.12,p=0.41)。
- SAP与再入院或复合并发症减少无关。
- 双侧唇裂亚组中,两SAP组SSI的OR分别为0.19和0.17(均p<0.05)。
临床怎么用
- 总体唇裂修复患儿无需常规预防性抗生素以降低SSI。
- 双侧唇裂修复患儿可考虑预防性抗生素以降低SSI风险。
局限性
- 回顾性队列设计,可能存在残余混杂。
- 双侧唇裂亚组样本量未报告,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cleft lip repair (CLR) is one of the most common reconstructive surgeries performed for congenital conditions. Although perioperative surgical antibiotic prophylaxis (SAP) is commonly used, evidence supporting its benefit in CLR is limited. METHODS: We performed a retrospective cohort study using the 2021-2024 American College of Surgeons Pediatric SAP Data Files. Infants ≤12 months who underwent primary CLR were categorized into three groups: no SAP, SAP without postoperative continuation, and SAP with continued postoperative IV antibiotics. Primary outcomes were 30-day SSI and readmission, which was evaluated using Firth penalized logistic regression. A prespecified subanalysis was performed in patients who underwent bilateral CLR (BCLR). RESULTS: A total of 4,966 patients met the inclusion criteria: 475 (9.6%) received no SAP, 3,250 (65.4%) received SAP without continuation, and 1,241 (25.0%) received SAP with postoperative continuation. SAP was administered to 90.4% of the patients, the most commonly used SAP was cefazolin (87.2%). The overall SSI rate was 0.7%. On multivariable analysis, neither SAP without continuation (OR 0.69, 95% CI 0.27-2.19, p=0.49) nor SAP with continuation (OR 0.61, 95% CI 0.20-2.12, p=0.41) were associated with decreased SSI. SAP was also not associated with reduced readmissions or composite complications. In the BCLR subanalysis, both SAP groups were significantly associated with decreased odds of SSI (OR 0.19 and 0.17, respectively; both p<0.05). CONCLUSIONS: In this multicenter cohort, SAP was not associated with reduced complications in the overall CLR population. However, patients who underwent BCLR and received SAP had significantly lower odds of SSI, indicating that this higher-risk subgroup may benefit from prophylaxis.
引用
- Gharavi A, Wan R, Haile D, et al. Prophylactic antibiotic use after cleft lip repair: Does it reduce complications, and is it necessary? J Plast Reconstr Aesthet Surg. 2026. PMID: 42697031. doi:10.1016/j.bjps.2026.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。